latonduine A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11440210 |
| CHEMBL ID | 5172255 |
| SCHEMBL ID | 13042347 |
| MeSH ID | M0455638 |
| Synonym |
|---|
| SCHEMBL13042347 |
| latonduine a |
| CHEMBL5172255 , |
| bdbm50594266 |
| latonduine |
| 12-amino-3,4-dibromo-5,8,11,13-tetrazatricyclo[8.4.0.02,6]tetradeca-1(14),2(6),3,10,12-pentaen-7-one |
| latonduine-a |
| GLXC-25264 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Protein mono-ADP-ribosyltransferase PARP16 | Homo sapiens (human) | IC50 (µMol) | 0.4270 | 0.4270 | 3.5519 | 5.1286 | AID1869186 |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | IC50 (µMol) | 3.4000 | 0.0035 | 1.1218 | 6.3000 | AID1869187 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1869186 | Inhibition of PARP16 (unknown origin) using IRE-1 as substrate incubated for 1 hr by chemiluminescence assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11 | Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules. |
| AID1869187 | Inhibition of recombinant human PARP3 using IRE-1 as substrate incubated for 1 hr by chemiluminescence assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11 | Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||